Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells

Mura, Simona; Hillaireau, Hervé; Nicolas, Julien; Droumaguet, Benjamin Le; Gueutin, Claire; Zanna, Sandrine; Tsapis, Nicolas; Fattal, Elias

doi:10.2147/ijn.s24552

Cited by 53 publications

(18 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, our alginate NPs showed a comparable cell viability (92% cell viability up to 250 µg/ml) as reported in previous studies (~90% viability at 50 µg/ml NP concentration, 24h incubation) using T47D breast cancer cells [42]. The higher cytocompatibility observed for PLGA-based NPs in our studies agrees with results by Mura et al[43], which showed more than 80% viability of Calu-3 cells incubated with PLGA and PLGA-CS NPs up to a concentration of 5 mg/ml for 24 h. These results indicate that all of our NP formulations are compatible with lung cells up to a high concentration of 1 mg/ml.…”

Section: Discussionsupporting

confidence: 92%

Polymeric nanoparticles for pulmonary protein and DNA delivery

et al. 2014

View full text Add to dashboard Cite

Polymeric nanoparticles (NPs) are promising carriers of biological agents to lung due to advantages including biocompatibility, ease of surface modification, localized action and reduced systemic toxicity. However, there have been no studies extensively characterizing and comparing the behavior of polymeric NPs for pulmonary protein/DNA delivery both in vitro and in vivo. We screened six polymeric NPs: gelatin, chitosan, alginate, poly lactic-co-glycolic acid (PLGA), PLGA-chitosan, and PLGA-polyethylene glycol (PEG), for inhalational protein/ DNA delivery. All NPs except PLGA-PEG and alginate were <300 nm in size with bi-phasic core compound release profile. Gelatin, PLGA NPs and PLGA-PEG NPs remained stable in deionized water, serum, saline and simulated lung fluid (Gamble’s solution) over 5 days. PLGA-based NPs and natural polymer NPs exhibited highest cytocompatibility and dose-dependent in vitro uptake respectively by human alveolar type-1 epithelial cells. Based on these profiles, gelatin and PLGA NPs were used to encapsulate a) plasmid DNA encoding yellow fluorescent protein (YFP) or b) rhodamine-conjugated erythropoietin (EPO) for inhalational delivery to rats. Following a single inhalation, widespread pulmonary EPO distribution persisted for up to 10 days while increasing YFP expression was observed for at least 7 days for both NPs. The overall results support both PLGA and gelatin NPs as promising carriers for pulmonary protein/DNA delivery.

show abstract

Section: Discussionsupporting

confidence: 92%

Polymeric nanoparticles for pulmonary protein and DNA delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…These values are well below the previously established size cutoff of 100 nm diameter required for effective penetration through the brain parenchyma (30). In addition, all formulations were shown to have slightly negative surface potentials (ranging from −2 to −9 mV), which are well within the range of 0 to −15mV that we and others previously have shown to be optimal for preventing aggregation of particles, and for minimizing toxicity to cell membranes (31, 32). …”

Section: Resultssupporting

confidence: 72%

Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas

King

Corso

Chen

et al. 2017

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

High-grade gliomas such as glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) are characterized by an aggressive phenotype with nearly universal local disease progression despite multimodal treatment, which typically includes chemotherapy, radiation therapy (RT), and possibly surgery. Radiosensitizers that have improved the effects of RT for extracranial tumors have been ineffective for the treatment of GBM and DIPG, in part due to poor blood brain barrier penetration and rapid intracranial clearance of small molecules. Here, we demonstrate that nanoparticles can provide sustained drug release and minimal toxicity. When administered locally, these nanoparticles conferred radiosensitization in vitro and improved survival in rats with intracranial gliomas when delivered concurrently with a 5-day course of fractionated RT. Compared to previous work using locally-delivered radiosensitizers and cranial radiation, our approach – based on rational selection of agents and a clinically-relevant radiation dosing schedule – produces the strongest synergistic effects between chemo- and radio-therapy approaches to the treatment of high-grade gliomas.

show abstract

“…PLGA nanoparticles have been widely studied owing to their excellent biocompatibility and cytotoxicity towards various cell lines and have been approved by FDA and European Medicine Agency for many drug delivery applications 34 . Mura et al investigated the lung toxicity of PLGA nanoparticles displaying various surface chemistry and surface charge on human bronchial Calu-3 cells 35 . PLGA nanoparticles were tuned by coating with chitosan, Poloxamer, and poly (vinyl alcohol) for grafting positive and negative as well as neutral charges.…”

Section: Discussionmentioning

confidence: 99%

Synergistic Effect of Cold Atmospheric Plasma and Drug Loaded Core-shell Nanoparticles on Inhibiting Breast Cancer Cell Growth

Zhu

Lee

Castro

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Nano-based drug delivery devices allowing for effective and sustained targeted delivery of therapeutic agents to solid tumors have revolutionized cancer treatment. As an emerging biomedical technique, cold atmospheric plasma (CAP), an ionized non-thermal gas mixture composed of various reactive oxygen species, reactive nitrogen species, and UV photons, shows great potential for cancer treatment. Here we seek to develop a new dual cancer therapeutic method by integrating promising CAP and novel drug loaded core-shell nanoparticles and evaluate its underlying mechanism for targeted breast cancer treatment. For this purpose, core-shell nanoparticles were synthesized via co-axial electrospraying. Biocompatible poly (lactic-co-glycolic acid) was selected as the polymer shell to encapsulate anti-cancer therapeutics. Results demonstrated uniform size distribution and high drug encapsulation efficacy of the electrosprayed nanoparticles. Cell studies demonstrated the effectiveness of drug loaded nanoparticles and CAP for synergistic inhibition of breast cancer cell growth when compared to each treatment separately. Importantly, we found CAP induced down-regulation of metastasis related gene expression (VEGF, MTDH, MMP9, and MMP2) as well as facilitated drug loaded nanoparticle uptake which may aid in minimizing drug resistance-a major problem in chemotherapy. Thus, the integration of CAP and drug encapsulated nanoparticles provides a promising tool for the development of a new cancer treatment strategy.

show abstract

Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells

Cited by 53 publications

References 56 publications

Polymeric nanoparticles for pulmonary protein and DNA delivery

Polymeric nanoparticles for pulmonary protein and DNA delivery

Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas

Synergistic Effect of Cold Atmospheric Plasma and Drug Loaded Core-shell Nanoparticles on Inhibiting Breast Cancer Cell Growth

Contact Info

Product

Resources

About